12:00 AM
 | 
Oct 20, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ABT-869: Completed Phase II enrollment

Last quarter, the partners completed enrollment of 134 patients in a Phase II trial evaluating oral ABT-869 as a single agent. Abbott partnered...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >